A Phase IV, Single-arm, Open-label Study of Sorafenib (Nexavar) in Advanced Hepatocellular Carcinoma (HCC).

Trial Profile

A Phase IV, Single-arm, Open-label Study of Sorafenib (Nexavar) in Advanced Hepatocellular Carcinoma (HCC).

Completed
Phase of Trial: Phase IV

Latest Information Update: 30 Oct 2013

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Liver cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms HATT
  • Sponsors Bayer
  • Most Recent Events

    • 01 Oct 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 02 Aug 2013 Planned end date changed from 1 Jun 2013 to 1 Oct 2013 as reported by ClinicalTrials.gov.
    • 13 May 2013 Planned end date changed from 1 Apr 2013 to 1 Jun 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top